{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:26:38Z","timestamp":1787037998317,"version":"build-2736575974"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Key Research Project of Sichuan Province","award":["2024YFFK0082"],"award-info":[{"award-number":["2024YFFK0082"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00228-026-04127-2","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:44:23Z","timestamp":1783651463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The pharmacokinetics and its covariates of rituximab in different clinical populations: a systematic review and narrative synthesis"],"prefix":"10.1007","volume":"82","author":[{"given":"Bo","family":"Zhenyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"4127_CR1","doi-asserted-by":"publisher","unstructured":"Weiner GJ (2010) Rituximab: mechanism of action[J]. Semin Hematol 47(2):115\u2009\u2013\u200923. https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.011","DOI":"10.1053\/j.seminhematol.2010.01.011"},{"issue":"1","key":"4127_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/157488708783330495","volume":"3","author":"J Rodriguez","year":"2008","unstructured":"Rodriguez J, Gutierrez A (2008) Pharmacokinetic properties of rituximab[J]. Rev Recen Clin Trial 3(1):22\u201330. https:\/\/doi.org\/10.2174\/157488708783330495","journal-title":"Rev Recen Clin Trial"},{"issue":"1","key":"4127_CR3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1186\/s12885-022-09772-1","volume":"22","author":"S Lara","year":"2022","unstructured":"Lara S, Heilig J, Virtanen A et al (2022) Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma[J]. BMC Cancer 22(1):678. https:\/\/doi.org\/10.1186\/s12885-022-09772-1","journal-title":"BMC Cancer"},{"issue":"3","key":"4127_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/25785826.2024.2448912","volume":"48","author":"C Ogita","year":"2025","unstructured":"Ogita C, Noguchi K, Takeuchi J et al (2025) Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study[J]. Immunological Med 48(3):203\u2013210. https:\/\/doi.org\/10.1080\/25785826.2024.2448912","journal-title":"Immunological Med"},{"key":"4127_CR5","doi-asserted-by":"publisher","unstructured":"Pekta\u015f G, Uncu \u0130A, Dere Y et al (2024) Retrospective Evaluation of Survival and Prognostic Factors in Immune Thrombocytopenia: A Single-Center and Cross-Sectional Study[J]. Med (Kaunas Lithuania) 60(7). https:\/\/doi.org\/10.3390\/medicina60071153","DOI":"10.3390\/medicina60071153"},{"key":"4127_CR6","doi-asserted-by":"publisher","first-page":"1671251","DOI":"10.3389\/fimmu.2025.1671251","volume":"16","author":"J Huang","year":"2025","unstructured":"Huang J, Yang Y, Wang Y et al (2025) Effectiveness and safety of rituximab monotherapy versus conventional regimens for adult idiopathic membranous nephropathy: real-world retrospective study[J]. Front Immunol 16:1671251. https:\/\/doi.org\/10.3389\/fimmu.2025.1671251","journal-title":"Front Immunol"},{"issue":"9950","key":"4127_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/s0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K et al (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial[J]. Lancet (London England) 384(9950):1273\u20131281. https:\/\/doi.org\/10.1016\/s0140-6736(14)60541-9","journal-title":"Lancet (London England)"},{"key":"4127_CR8","doi-asserted-by":"publisher","first-page":"1561214","DOI":"10.3389\/fimmu.2025.1561214","volume":"16","author":"X Zheng","year":"2025","unstructured":"Zheng X, Di J, Chen X et al (2025) Meta-analysis of the efficacy and safety of rituximab in the treatment of primary Sj\u00f6gren\u2019s syndrome[J]. Front Immunol 16:1561214. https:\/\/doi.org\/10.3389\/fimmu.2025.1561214","journal-title":"Front Immunol"},{"key":"4127_CR9","doi-asserted-by":"publisher","first-page":"1599473","DOI":"10.3389\/fimmu.2025.1599473","volume":"16","author":"H Wang","year":"2025","unstructured":"Wang H, Zhao L, Yang S et al (2025) Rituximab as the first-line treatment in newly diagnosed systemic lupus erythematosus[J]. Front Immunol 16:1599473. https:\/\/doi.org\/10.3389\/fimmu.2025.1599473","journal-title":"Front Immunol"},{"issue":"1","key":"4127_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.critrevonc.2006.09.004","volume":"62","author":"G Cartron","year":"2007","unstructured":"Cartron G, Blasco H, Paintaud G et al (2007) Pharmacokinetics of rituximab and its clinical use: thought for the best use?[J]. Crit Rev Oncol\/Hematol 62(1):43\u201352. https:\/\/doi.org\/10.1016\/j.critrevonc.2006.09.004","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"9","key":"4127_CR11","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1023\/a:1008416911099","volume":"9","author":"NL Berinstein","year":"1998","unstructured":"Berinstein NL, Grillo-L\u00f3pez AJ, White CA et al (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma[J]. Annals oncology: official J Eur Soc Med Oncol 9(9):995\u20131001. https:\/\/doi.org\/10.1023\/a:1008416911099","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"4","key":"4127_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41401-020-0479-2","volume":"42","author":"S Liu","year":"2021","unstructured":"Liu S, Huang H, Chen RX et al (2021) Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1\/2[J]. Acta Pharmacol Sin 42(4):641\u2013647. https:\/\/doi.org\/10.1038\/s41401-020-0479-2","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"4127_CR13","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/cts.13186","volume":"15","author":"S Liu","year":"2022","unstructured":"Liu S, Wang Z, Chen R et al (2022) Rituximab exposure-response in triweekly R-CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes[J]. Clin Transl Sci 15(3):680\u2013690. https:\/\/doi.org\/10.1111\/cts.13186","journal-title":"Clin Transl Sci"},{"issue":"8","key":"4127_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/psp4.12665","volume":"10","author":"E Gibiansky","year":"2021","unstructured":"Gibiansky E, Gibiansky L, Chavanne C et al (2021) Population pharmacokinetic and exposure-response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia[J]. CPT: pharmacometrics Syst Pharmacol 10(8):914\u2013927. https:\/\/doi.org\/10.1002\/psp4.12665","journal-title":"CPT: pharmacometrics Syst Pharmacol"},{"issue":"8","key":"4127_CR15","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","volume":"34","author":"S Boyer-Suavet","year":"2019","unstructured":"Boyer-Suavet S, Andreani M, Cremoni M et al (2019) Rituximab bioavailability in primary membranous nephropathy[J]. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association -. Eur Ren Association 34(8):1423\u20131425. https:\/\/doi.org\/10.1093\/ndt\/gfz041","journal-title":"Eur Ren Association"},{"issue":"9","key":"4127_CR16","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1177\/0091270007305297","volume":"47","author":"F Breedveld","year":"2007","unstructured":"Breedveld F, Agarwal S, Yin M et al (2007) Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response[J]. J Clin Pharmacol 47(9):1119\u20131128. https:\/\/doi.org\/10.1177\/0091270007305297","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"4127_CR17","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4161\/mabs.26008","volume":"5","author":"J Golay","year":"2013","unstructured":"Golay J, Semenzato G, Rambaldi A et al (2013) Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics[J]. mAbs 5(6):826\u2013837. https:\/\/doi.org\/10.4161\/mabs.26008","journal-title":"mAbs"},{"issue":"6","key":"4127_CR18","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","volume":"51","author":"A Harjunp\u00e4\u00e4","year":"2000","unstructured":"Harjunp\u00e4\u00e4 A, Junnikkala S, Meri S (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms[J]. Scand J Immunol 51(6):634\u2013641. https:\/\/doi.org\/10.1046\/j.1365-3083.2000.00745.x","journal-title":"Scand J Immunol"},{"issue":"9","key":"4127_CR19","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood.v98.9.2771","volume":"98","author":"B Bellosillo","year":"2001","unstructured":"Bellosillo B, Villamor N, L\u00f3pez-Guillermo A et al (2001) Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species[J]. Blood 98(9):2771\u20132777. https:\/\/doi.org\/10.1182\/blood.v98.9.2771","journal-title":"Blood"},{"issue":"2","key":"4127_CR20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/art.10764","volume":"48","author":"JH Anolik","year":"2003","unstructured":"Anolik JH, Campbell D, Felgar RE et al (2003) The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus[J]. Arthritis Rheum 48(2):455\u2013459. https:\/\/doi.org\/10.1002\/art.10764","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4127_CR21","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"DG Maloney","year":"1994","unstructured":"Maloney DG, Liles TM, Czerwinski DK et al (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma[J]. Blood 84(8):2457\u20132466","journal-title":"Blood"},{"issue":"10","key":"4127_CR22","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/jco.1997.15.10.3266","volume":"15","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, Bodkin DJ et al (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma[J]. J Clin oncology: official J Am Soc Clin Oncol 15(10):3266\u20133274. https:\/\/doi.org\/10.1200\/jco.1997.15.10.3266","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"1","key":"4127_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41598-017-17934-6","volume":"8","author":"C Schoergenhofer","year":"2018","unstructured":"Schoergenhofer C, Schwameis M, Firbas C et al (2018) Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing[J]. Sci Rep 8(1):124. https:\/\/doi.org\/10.1038\/s41598-017-17934-6","journal-title":"Sci Rep"},{"key":"4127_CR24","doi-asserted-by":"publisher","unstructured":"Zaja F, Vianelli N, Volpetti S et al (2010) Low-dose rituximab in adult patients with primary immune thrombocytopenia[J]. Eur J Haematol 85(4):329\u2009\u2013\u200934. https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01486.x","DOI":"10.1111\/j.1600-0609.2010.01486.x"},{"issue":"4","key":"4127_CR25","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/ajh.26473","volume":"97","author":"X Ni","year":"2022","unstructured":"Ni X, Li D, Yuan C et al (2022) Single-dose versus low-dose rituximab in corticosteroid-resistant or relapsed ITP: A multicenter, randomized, controlled study[J]. Am J Hematol 97(4):440\u2013447. https:\/\/doi.org\/10.1002\/ajh.26473","journal-title":"Am J Hematol"},{"issue":"11","key":"4127_CR26","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3760\/cma.j.cn112140-20220418-00340","volume":"60","author":"XJ Zhu","year":"2022","unstructured":"Zhu XJ, Ma JY, Chen ZP et al (2022) [Comparison of the efficacy and safety of 2 low-dose rituximab regimens in the second-line treatment of primary immune thrombocytopenia in children][J]. Zhonghua er ke za zhi\u2009=\u2009Chinese. J Pediatr 60(11):1185\u20131190. https:\/\/doi.org\/10.3760\/cma.j.cn112140-20220418-00340","journal-title":"J Pediatr"},{"issue":"7","key":"4127_CR27","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jfma.2024.06.013","volume":"124","author":"C Wang","year":"2025","unstructured":"Wang C, Zhang MZ, Li LX et al (2025) Ultra-low-dose rituximab is effective for the treatment of patients with minimal change disease - A retrospective study[J]. J Formos Med Association = Taiwan yi zhi 124(7):633\u2013637. https:\/\/doi.org\/10.1016\/j.jfma.2024.06.013","journal-title":"J Formos Med Association = Taiwan yi zhi"},{"key":"4127_CR28","doi-asserted-by":"publisher","unstructured":"Sinha R, Pradhan S, Raut S et al (2025) Single (375\u00a0mg\/m(2)) vs. double dose of rituximab along with mycophenolate mofetil for children with steroid-dependent\/frequently relapsing nephrotic syndrome: a multicentre open-label randomized controlled trial[J]. Pediatric nephrology (Berlin, Germany) 40(4):995\u20131004. https:\/\/doi.org\/10.1007\/s00467-024-06619-8","DOI":"10.1007\/s00467-024-06619-8"},{"issue":"2","key":"4127_CR29","doi-asserted-by":"publisher","first-page":"2427173","DOI":"10.1080\/0886022x.2024.2427173","volume":"46","author":"XL Niu","year":"2024","unstructured":"Niu XL, Gu YF, Feng D et al (2024) Long Term Evaluations of First Single-dose Rituximab in Children with Steroid-Dependent Minimal-Change Nephrotic Syndrome[J]. Ren Fail 46(2):2427173. https:\/\/doi.org\/10.1080\/0886022x.2024.2427173","journal-title":"Ren Fail"},{"issue":"8","key":"4127_CR30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00467-020-04540-4","volume":"35","author":"P Ravani","year":"2020","unstructured":"Ravani P, Lugani F, Pisani I et al (2020) Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study[J]. Pediatr Nephrol 35(8):1437\u20131444. https:\/\/doi.org\/10.1007\/s00467-020-04540-4","journal-title":"Pediatr Nephrol"},{"key":"4127_CR31","doi-asserted-by":"publisher","first-page":"1197651","DOI":"10.3389\/fphar.2024.1197651","volume":"15","author":"H Liang","year":"2024","unstructured":"Liang H, Deng Z, Niu S et al (2024) Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study[J]. Front Pharmacol 15:1197651. https:\/\/doi.org\/10.3389\/fphar.2024.1197651","journal-title":"Front Pharmacol"},{"issue":"3","key":"4127_CR32","doi-asserted-by":"publisher","first-page":"328","DOI":"10.14744\/cpr.2025.96241","volume":"47","author":"S Meedimale","year":"2025","unstructured":"Meedimale S, Panda SS, Panda AK et al (2025) Experience of Using a Bruton Tyrosine Kinase (BTK) Inhibitor in Primary Testicular Diffuse Large B-Cell Lymphoma (DLBCL) with Isolated Central Nervous System (CNS) Metastasis[J]. J Clin Pract Res 47(3):328\u2013331. https:\/\/doi.org\/10.14744\/cpr.2025.96241","journal-title":"J Clin Pract Res"},{"issue":"4","key":"4127_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/1060028018803587","volume":"53","author":"U Fogueri","year":"2019","unstructured":"Fogueri U, Cheungapasitporn W, Bourne D et al (2019) Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy[J]. Annals pharmacotherapy 53(4):357\u2013363. https:\/\/doi.org\/10.1177\/1060028018803587","journal-title":"Annals pharmacotherapy"},{"issue":"12","key":"4127_CR34","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1177\/0091270011430506","volume":"52","author":"J Li","year":"2012","unstructured":"Li J, Zhi J, Wenger M et al (2012) Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia[J]. J Clin Pharmacol 52(12):1918\u20131926. https:\/\/doi.org\/10.1177\/0091270011430506","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"4127_CR35","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/bjh.14802","volume":"178","author":"T Str\u00fc\u00dfmann","year":"2017","unstructured":"Str\u00fc\u00dfmann T, Fritsch K, Baumgarten A et al (2017) Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation[J]. Br J Haematol 178(6):927\u2013935. https:\/\/doi.org\/10.1111\/bjh.14802","journal-title":"Br J Haematol"},{"key":"4127_CR36","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","volume":"368","author":"M Campbell","year":"2020","unstructured":"Campbell M, Mckenzie JE, Sowden A et al (2020) Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline[J]. BMJ (Clinical Res ed) 368:l6890. https:\/\/doi.org\/10.1136\/bmj.l6890","journal-title":"BMJ (Clinical Res ed)"},{"key":"4127_CR37","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.26633\/rpsp.2022.112","volume":"46","author":"MJ Page","year":"2022","unstructured":"Page MJ, Mckenzie JE, Bossuyt PM et al (2022) [The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsDeclaraci\u00f3n PRISMA 2020: una gu\u00eda actualizada para la publicaci\u00f3n de revisiones sistem\u00e1ticas][J]. Revista panamericana de salud publica\u2009=\u2009Pan. Am J Public Health 46:e112. https:\/\/doi.org\/10.26633\/rpsp.2022.112","journal-title":"Am J Public Health"},{"key":"4127_CR38","doi-asserted-by":"publisher","unstructured":"Kanji S, Hayes M, Ling A et al (2015) Reporting guidelines for clinical pharmacokinetic studies: The ClinPK Statement[J]. Clin Pharmacokinet 54(7):783\u2009\u2013\u200995. https:\/\/doi.org\/10.1007\/s40262-015-0236-8","DOI":"10.1007\/s40262-015-0236-8"},{"issue":"5","key":"4127_CR39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1365-2125.2007.02975.x","volume":"64","author":"C Dartois","year":"2007","unstructured":"Dartois C, Brendel K, Comets E et al (2007) Overview of model-building strategies in population PK\/PD analyses: 2002\u20132004 literature survey[J]. Br J Clin Pharmacol 64(5):603\u2013612. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02975.x","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"4127_CR40","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/bcp.14272","volume":"86","author":"MH Abdel Jalil","year":"2020","unstructured":"Abdel Jalil MH, Abdullah N, Alsous MM et al (2020) A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population[J]. Br J Clin Pharmacol 86(7):1267\u20131280. https:\/\/doi.org\/10.1111\/bcp.14272","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4127_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2165\/00003088-200746030-00003","volume":"46","author":"K Brendel","year":"2007","unstructured":"Brendel K, Dartois C, Comets E et al (2007) Are population pharmacokinetic and\/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004[J]. Clin Pharmacokinet 46(3):221\u2013234. https:\/\/doi.org\/10.2165\/00003088-200746030-00003","journal-title":"Clin Pharmacokinet"},{"key":"4127_CR42","doi-asserted-by":"publisher","unstructured":"Shi Y, Zhang Q, Han X et al (2021) Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma[J]. Chin J Cancer Res\u2009=\u2009Chung-kuo yen cheng yen chiu 33(3):405\u2013416. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2021.03.11","DOI":"10.21147\/j.issn.1000-9604.2021.03.11"},{"issue":"3","key":"4127_CR43","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1016\/s2352-3026(16)00004-1","volume":"3","author":"S Assouline","year":"2016","unstructured":"Assouline S, Buccheri V, Delmer A et al (2016) Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial[J]. Lancet Haematol 3(3):e128\u2013e138. https:\/\/doi.org\/10.1016\/s2352-3026(16)00004-1","journal-title":"Lancet Haematol"},{"issue":"5","key":"4127_CR44","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","volume":"123","author":"M Pfreundschuh","year":"2014","unstructured":"Pfreundschuh M, M\u00fcller C, Zeynalova S et al (2014) Suboptimal dosing of rituximab in male and female patients with DLBCL[J]. Blood 123(5):640\u2013646. https:\/\/doi.org\/10.1182\/blood-2013-07-517037","journal-title":"Blood"},{"issue":"5","key":"4127_CR45","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1023\/a:1008265313133","volume":"9","author":"K Tobinai","year":"1998","unstructured":"Tobinai K, Kobayashi Y, Narabayashi M et al (1998) Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group[J]. Annals oncology: official J Eur Soc Med Oncol 9(5):527\u2013534. https:\/\/doi.org\/10.1023\/a:1008265313133","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"5","key":"4127_CR46","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/bcp.12662","volume":"80","author":"S Assouline","year":"2015","unstructured":"Assouline S, Buccheri V, Delmer A et al (2015) Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia[J]. Br J Clin Pharmacol 80(5):1001\u20131009. https:\/\/doi.org\/10.1111\/bcp.12662","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"4127_CR47","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/10428194.2024.2439525","volume":"66","author":"Y Gao","year":"2025","unstructured":"Gao Y, Zhang L, Gao S et al (2025) Pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab in previously untreated Chinese patients with CD20\u2009+\u2009diffuse large B-cell lymphoma: a phase II randomized controlled trial[J]. Leuk Lymphoma 66(4):680\u2013690. https:\/\/doi.org\/10.1080\/10428194.2024.2439525","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"4127_CR48","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1078-0432.Ccr-13-0474","volume":"20","author":"C Kadoch","year":"2014","unstructured":"Kadoch C, Li J, Wong VS et al (2014) Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma[J]. Clin cancer research: official J Am Association Cancer Res 20(4):1029\u20131041. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0474","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"9","key":"4127_CR49","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/bcp.13991","volume":"85","author":"D Ternant","year":"2019","unstructured":"Ternant D, Monjanel H, Venel Y et al (2019) Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: A pilot study[J]. Br J Clin Pharmacol 85(9):2002\u20132010. https:\/\/doi.org\/10.1111\/bcp.13991","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"4127_CR50","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/psp4.12885","volume":"12","author":"RJ Svensson","year":"2023","unstructured":"Svensson RJ, Ooi QX, Friberg LE et al (2023) Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity[J]. CPT: pharmacometrics Syst Pharmacol 12(2):154\u2013167. https:\/\/doi.org\/10.1002\/psp4.12885","journal-title":"CPT: pharmacometrics Syst Pharmacol"},{"issue":"4","key":"4127_CR51","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40262-019-00826-5","volume":"59","author":"A Bensalem","year":"2020","unstructured":"Bensalem A, Mulleman D, Paintaud G et al (2020) Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited[J]. Clin Pharmacokinet 59(4):519\u2013530. https:\/\/doi.org\/10.1007\/s40262-019-00826-5","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"4127_CR52","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3324\/haematol.2011.059246","volume":"97","author":"U J\u00e4ger","year":"2012","unstructured":"J\u00e4ger U, Fridrik M, Zeitlinger M et al (2012) Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response[J]. Haematologica 97(9):1431\u20131438. https:\/\/doi.org\/10.3324\/haematol.2011.059246","journal-title":"Haematologica"},{"issue":"8","key":"4127_CR53","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1111\/bcp.13271","volume":"83","author":"S Rozman","year":"2017","unstructured":"Rozman S, Grabnar I, Novakovi\u0107 S et al (2017) Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome[J]. Br J Clin Pharmacol 83(8):1782\u20131790. https:\/\/doi.org\/10.1111\/bcp.13271","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"4127_CR54","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11095-019-2605-8","volume":"36","author":"SM Lavezzi","year":"2019","unstructured":"Lavezzi SM, De Jong J, Neyens M et al (2019) Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial[J]. Pharm Res 36(7):93. https:\/\/doi.org\/10.1007\/s11095-019-2605-8","journal-title":"Pharm Res"},{"issue":"5","key":"4127_CR55","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s10067-020-04996-7","volume":"39","author":"L Bergantini","year":"2020","unstructured":"Bergantini L, D\u2019alessandro M, Cameli P et al (2020) Effects of rituximab therapy on B cell differentiation and depletion[J]. Clin Rheumatol 39(5):1415\u20131421. https:\/\/doi.org\/10.1007\/s10067-020-04996-7","journal-title":"Clin Rheumatol"},{"issue":"5","key":"4127_CR56","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1472-8206.2009.00714.x","volume":"23","author":"H Blasco","year":"2009","unstructured":"Blasco H, Chatelut E, De Bretagne IB et al (2009) Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma[J]. Fundam Clin Pharmacol 23(5):601\u2013608. https:\/\/doi.org\/10.1111\/j.1472-8206.2009.00714.x","journal-title":"Fundam Clin Pharmacol"},{"issue":"14","key":"4127_CR57","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","volume":"119","author":"C M\u00fcller","year":"2012","unstructured":"M\u00fcller C, Murawski N, Wiesen MH et al (2012) The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL[J]. Blood 119(14):3276\u20133284. https:\/\/doi.org\/10.1182\/blood-2011-09-380949","journal-title":"Blood"},{"issue":"2","key":"4127_CR58","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00280-016-3083-x","volume":"78","author":"V Gota","year":"2016","unstructured":"Gota V, Karanam A, Rath S et al (2016) Population pharmacokinetics of Reditux\u2122, a biosimilar Rituximab, in diffuse large B-cell lymphoma[J]. Cancer Chemother Pharmacol 78(2):353\u2013359. https:\/\/doi.org\/10.1007\/s00280-016-3083-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4127_CR59","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-018-3524-9","volume":"81","author":"M Candelaria","year":"2018","unstructured":"Candelaria M, Gonzalez D, Fern\u00e1ndez G\u00f3mez FJ et al (2018) Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83\u2122, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach[J]. Cancer Chemother Pharmacol 81(3):515\u2013527. https:\/\/doi.org\/10.1007\/s00280-018-3524-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"19","key":"4127_CR60","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1182\/blood-2016-10-744292","volume":"129","author":"M Tout","year":"2017","unstructured":"Tout M, Casasnovas O, Meignan M et al (2017) Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report[J]. Blood 129(19):2616\u20132623. https:\/\/doi.org\/10.1182\/blood-2016-10-744292","journal-title":"Blood"},{"issue":"8","key":"4127_CR61","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/bcp.13270","volume":"83","author":"B Lioger","year":"2017","unstructured":"Lioger B, Edupuganti SR, Mulleman D et al (2017) Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients[J]. Br J Clin Pharmacol 83(8):1773\u20131781. https:\/\/doi.org\/10.1111\/bcp.13270","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"4127_CR62","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/0091270005277075","volume":"45","author":"CM Ng","year":"2005","unstructured":"Ng CM, Bruno R, Combs D et al (2005) Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial[J]. J Clin Pharmacol 45(7):792\u2013801. https:\/\/doi.org\/10.1177\/0091270005277075","journal-title":"J Clin Pharmacol"},{"key":"4127_CR63","doi-asserted-by":"publisher","first-page":"725665","DOI":"10.3389\/fphar.2021.725665","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Shen Q, Dong M et al (2021) Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome[J]. Front Pharmacol 12:725665. https:\/\/doi.org\/10.3389\/fphar.2021.725665","journal-title":"Front Pharmacol"},{"issue":"5","key":"4127_CR64","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/bcp.12098","volume":"76","author":"F Puisset","year":"2013","unstructured":"Puisset F, White-Koning M, Kamar N et al (2013) Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease[J]. Br J Clin Pharmacol 76(5):734\u2013740. https:\/\/doi.org\/10.1111\/bcp.12098","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"4127_CR65","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1111\/cts.13351","volume":"15","author":"C Jamois","year":"2022","unstructured":"Jamois C, Gibiansky L, Chavanne C et al (2022) Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis[J]. Clin Transl Sci 15(9):2172\u20132183. https:\/\/doi.org\/10.1111\/cts.13351","journal-title":"Clin Transl Sci"},{"key":"4127_CR66","doi-asserted-by":"publisher","unstructured":"Hartinger JM, \u0160\u00edma M, Hru\u0161kov\u00e1 Z et al (2024) A novel dosing approach for rituximab in glomerular diseases based on a population pharmacokinetic analysis[J]. Biomed Pharmacother\u2009=\u2009Biomedecine & pharmacotherapie 175:116655. https:\/\/doi.org\/10.1016\/j.biopha.2024.116655","DOI":"10.1016\/j.biopha.2024.116655"},{"key":"4127_CR67","doi-asserted-by":"publisher","unstructured":"Del Vecchio L, Allinovi M, Rocco P et al (2021) Rituximab therapy for adults with nephrotic syndromes: standard schedules or B cell-targeted therapy?[J]. J Clin Med 10(24). https:\/\/doi.org\/10.3390\/jcm10245847","DOI":"10.3390\/jcm10245847"},{"issue":"5","key":"4127_CR68","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10928-007-9065-1","volume":"34","author":"A Garg","year":"2007","unstructured":"Garg A, Balthasar JP (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice[J]. J Pharmacokinet Pharmacodyn 34(5):687\u2013709. https:\/\/doi.org\/10.1007\/s10928-007-9065-1","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"4127_CR69","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1046\/j.1365-2567.1996.d01-775.x","volume":"89","author":"EJ Israel","year":"1996","unstructured":"Israel EJ, Wilsker DF, Hayes KC et al (1996) Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn[J]. Immunology 89(4):573\u2013578. https:\/\/doi.org\/10.1046\/j.1365-2567.1996.d01-775.x","journal-title":"Immunology"},{"issue":"4","key":"4127_CR70","doi-asserted-by":"publisher","first-page":"614","DOI":"10.4161\/mabs.24815","volume":"5","author":"C Passot","year":"2013","unstructured":"Passot C, Azzopardi N, Renault S et al (2013) Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies[J]. mAbs 5(4):614\u2013619. https:\/\/doi.org\/10.4161\/mabs.24815","journal-title":"mAbs"},{"issue":"11","key":"4127_CR71","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s40262-025-01549-6","volume":"64","author":"D Ternant","year":"2025","unstructured":"Ternant D, Le Tilly O, Cartron G et al (2025) Immunoglobulin G Receptors (Fc\u03b3R), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab Pharmacokinetics[J]. Clin Pharmacokinet 64(11):1639\u20131654. https:\/\/doi.org\/10.1007\/s40262-025-01549-6","journal-title":"Clin Pharmacokinet"},{"key":"4127_CR72","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-3-319-07911-0_12","volume":"382","author":"DK Challa","year":"2014","unstructured":"Challa DK, Velmurugan R, Ober RJ et al (2014) FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions[J]. Curr Top Microbiol Immunol 382:249\u2013272. https:\/\/doi.org\/10.1007\/978-3-319-07911-0_12","journal-title":"Curr Top Microbiol Immunol"},{"issue":"11","key":"4127_CR73","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","volume":"93","author":"RP Junghans","year":"1996","unstructured":"Junghans RP, Anderson CL (1996) The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor[J]. Proc Natl Acad Sci USA 93(11):5512\u20135516. https:\/\/doi.org\/10.1073\/pnas.93.11.5512","journal-title":"Proc Natl Acad Sci USA"},{"key":"4127_CR74","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/2031352a0","volume":"203","author":"FW Brambell","year":"1964","unstructured":"Brambell FW, Hemmings WA, Morris IG, A THEORETICAL MODEL, OF GAMMA-GLOBULIN CATABOLISM[J] (1964) Nature 203:1352\u20131354. https:\/\/doi.org\/10.1038\/2031352a0","journal-title":"Nature"},{"issue":"4","key":"4127_CR75","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/rheumatology\/kex484","volume":"57","author":"D Cornec","year":"2018","unstructured":"Cornec D, Kabat BF, Mills JR et al (2018) Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis[J]. Rheumatology (Oxford) 57(4):639\u2013650. https:\/\/doi.org\/10.1093\/rheumatology\/kex484","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"4127_CR76","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1136\/annrheumdis-2016-209540","volume":"76","author":"DH Yoo","year":"2017","unstructured":"Yoo DH, Suh CH, Shim SC et al (2017) A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis[J]. Ann Rheum Dis 76(3):566\u2013570. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209540","journal-title":"Ann Rheum Dis"},{"key":"4127_CR77","doi-asserted-by":"publisher","unstructured":"Haridas VM, Katta R, Nalawade A et al (2020) Pharmacokinetic similarity and comparative pharmacodynamics, safety, efficacy, and immunogenicity of DRL_RI versus reference rituximab in biologics-na\u00efve patients with moderate-to-severe rheumatoid arthritis: a double-blind, randomized, three-arm study[J]. BioDrugs 34(2): 183\u2009\u2013\u200996. https:\/\/doi.org\/10.1007\/s40259-020-00406-1","DOI":"10.1007\/s40259-020-00406-1"},{"issue":"1","key":"4127_CR78","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/bcp.12916","volume":"82","author":"S Cohen","year":"2016","unstructured":"Cohen S, Emery P, Greenwald M et al (2016) A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis[J]. Br J Clin Pharmacol 82(1):129\u2013138. https:\/\/doi.org\/10.1111\/bcp.12916","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"4127_CR79","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1136\/annrheumdis-2017-211281","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Cohen SB, Tony HP et al (2017) A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis[J]. Ann Rheum Dis 76(9):1598\u20131602. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211281","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4127_CR80","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1080\/19420862.2018.1487912","volume":"10","author":"W Park","year":"2018","unstructured":"Park W, Bo\u017ei\u0107-Majstorovi\u0107 L, Milakovic D et al (2018) Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial[J]. mAbs 10(6):934\u2013943. https:\/\/doi.org\/10.1080\/19420862.2018.1487912","journal-title":"mAbs"},{"issue":"1","key":"4127_CR81","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/hon.2693","volume":"38","author":"IV Poddubnaya","year":"2020","unstructured":"Poddubnaya IV, Alekseev SM, Kaplanov KD et al (2020) Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial[J]. Hematol Oncol 38(1):67\u201373. https:\/\/doi.org\/10.1002\/hon.2693","journal-title":"Hematol Oncol"},{"issue":"6","key":"4127_CR82","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00280-023-04530-x","volume":"91","author":"A Patel","year":"2023","unstructured":"Patel A, Bhatt N, Prakash SS et al (2023) Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India[J]. Cancer Chemother Pharmacol 91(6):457\u2013468. https:\/\/doi.org\/10.1007\/s00280-023-04530-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"4127_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jgo.19.00248","volume":"5","author":"A Viswabandya","year":"2019","unstructured":"Viswabandya A, Shah S, Mukhopadhyay A et al (2019) Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma[J]. J global Oncol 5:1\u201313. https:\/\/doi.org\/10.1200\/jgo.19.00248","journal-title":"J global Oncol"},{"issue":"6","key":"4127_CR84","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1097\/hs9.0000000000000323","volume":"3","author":"J Gribben","year":"2019","unstructured":"Gribben J, Merlini G, Hagenbeek A (2019) Here to Stay: Biosimilars in Hematology[J]. HemaSphere 3(6):e323. https:\/\/doi.org\/10.1097\/hs9.0000000000000323","journal-title":"HemaSphere"},{"key":"4127_CR85","doi-asserted-by":"crossref","unstructured":"Mulcahy AW, Hlavka JP, Case SR (2018) Biosimilar cost savings in the United States: initial experience and future potential[J]. Rand Health Q 7(4):3","DOI":"10.7249\/rhq-07-04-03"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04127-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04127-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04127-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:55:20Z","timestamp":1787036120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04127-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":85,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4127"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04127-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"197"}}